Gemcitabine and the blood brain barrier

被引：10

作者：

Davis, JR

Fernandes, C

Zalcberg, JR

机构：

[1] Peter MacCallum Canc Inst, Div Haematol & Med Oncol, Melbourne, Vic 8006, Australia

[2] Peter MacCallum Canc Inst, Dept Pharm, Melbourne, Vic 8006, Australia

来源：

AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE | 1999年 / 29卷 / 06期

关键词：

D O I：

10.1111/j.1445-5994.1999.tb00795.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：831 / 832

页数：2

共 6 条

[1] Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study [J].

Crino, L ;

Scagliotti, G ;

Marangolo, M ;

Figoli, F ;

Clerici, M ;

DeMarinis, F ;

Salvati, F ;

Cruciani, G ;

Dogliotti, L ;

Pucci, F ;

Paccagnella, A ;

Adamo, V ;

Altavilla, G ;

Incoronato, P ;

Trippetti, M ;

Mosconi, AM ;

Santucci, A ;

Sorbolini, S ;

Oliva, C ;

Tonato, M .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :297-303

[2]

DORR RT, 1994, CYTARABINE CANC CHEM, P331

[3]

GORNLEY PE, 1981, CANCER CHEMOTH PHARM, V5, P257

[4] Gemcitabine - A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer [J].

Noble, S ;

Goa, KL .

DRUGS, 1997, 54 (03) :447-472

[5] Preclinical characteristics of gemcitabine [J].

Plunkett, W ;

Huang, P ;

Gandhi, V .

ANTI-CANCER DRUGS, 1995, 6 :7-13

[6] Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study [J].

Wozniak, AJ ;

Crowley, JJ ;

Balcerzak, SP ;

Weiss, GR ;

Spiridonidis, CH ;

Baker, LH ;

Albain, KS ;

Kelly, K ;

Taylor, SA ;

Gandara, DR ;

Livingston, RB .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2459-2465

← 1 →